Podcast: Play in new window | Download
Summary
In this solo episode, Allan breaks down the fight playing out right now in Washington, DC between GLP-1 medications and peptides. The two keep getting mentioned in the same breath, but they sit on opposite sides of the evidence line. GLP-1s like semaglutide and tirzepatide are tested medications with known dosing and documented side effects. Peptides like BPC-157 and TB-500, the so-called Wolverine stack, are not approved for human use and live in a gray market built mostly on rat studies and anecdote. Allan walks through the recent FDA Pharmacy Compounding Advisory Committee panel that recommended approving 6 of 7 peptides even after the agency’s own scientists raised safety concerns, and he points out that the panel was largely made up of people who profit from compounding and selling them. His bottom line: ignore the branding, follow the science, and make the choice that is safe and right for you.
Links
- Work with Allan one-on-one (a few coaching slots are open right now): coach@40plusfitness.com
- Allan’s book, The Wellness Roadmap
- 40+ Fitness: https://40plusfitness.com
Key Takeaways
- GLP-1s and peptides keep getting named together, but Allan draws a hard line between them. GLP-1s (semaglutide, tirzepatide) are regulated medications with clinical trials, dosing schedules, and documented side effects. Peptides like BPC-157 and TB-500 are not approved for human consumption and rest mostly on animal studies and anecdote.
- Allan’s core argument is that the loudest words in this debate are branding, not science. “Ozempic face,” “miracle drug,” “cheating,” and “rat chemicals” are built to be memorable and to provoke a reaction. He wants you following the data, not the soundbite.
- He flags a real conflict of interest in the FDA Pharmacy Compounding Advisory Committee that met on July 23 and 24. It recommended approving 6 of 7 peptides for human compounding even though the FDA’s own scientists had just warned of inadequate evidence and safety concerns, and the panel was largely composed of the people who make money compounding and selling those same peptides.
- His caution is personal and specific. With almost no human safety data, some peptides could in theory speed tumor growth. Coming off stage 3 cancer and in immunotherapy, Allan says he will not go near them, while making clear that is a decision he is making for himself.
- On self-experimentation, Allan backs the N=1 approach only when the downside is small. An injectable with unknown quality, unknown safety, and an unknown effect does not qualify, so for now his answer on peptides is simple: he is out until there is real human data.
“Don’t let the branding pull you away from the science. The science is what the science is.”
Coach Allan
Another Episode You May Enjoy
Episode Notes
Podcast: 40+ Fitness
Episode: 758
Published: 2026-08-04
Host: Allan Misner (aka Coach Allan), author of The Wellness Roadmap
Listen & Subscribe: Apple Podcasts · Spotify · YouTube (audio only)